1
NR 565 FINAL EXAM ADVANCED PHARMACOLOGY
2026/2027 | 220 Questions with Detailed Verified Answers |
100% Correct | Already Graded A+ | Pass Guaranteed
[Domain 1: Pharmacokinetics & Pharmacodynamics (Questions 1-25)]
[1A: ADME Processes (Absorption, Distribution, Metabolism, Excretion) -
Questions 1-12]
Q1. A 78-year-old patient with atrophic gastritis is prescribed oral vitamin B12
supplementation. The APRN recognizes that this patient's medication absorption will
be significantly impaired due to which physiological change?
A. Increased gastric motility causing rapid transit time
B. Decreased gastric acid production leading to reduced intrinsic factor
C. Increased intestinal blood flow enhancing first-pass metabolism
D. Decreased bile salt production affecting fat-soluble vitamin uptake
Correct Answer: B. Decreased gastric acid production leading to reduced intrinsic
factor [CORRECT]
Rationale: Atrophic gastritis reduces parietal cell mass, decreasing intrinsic factor
secretion required for B12 absorption; options A, C, and D do not accurately describe
the primary pathophysiology of B12 malabsorption in this condition.
Q2. A patient with severe hypoalbuminemia (albumin 2.1 g/dL) is prescribed warfarin.
The APRN anticipates that the free fraction of this highly protein-bound drug will
increase, potentially causing:
A. Decreased therapeutic effect requiring dose escalation
B. Increased risk of bleeding due to higher unbound active drug concentration
C. Reduced hepatic metabolism requiring less frequent dosing
D. Enhanced renal excretion necessitating hydration protocols
Correct Answer: B. Increased risk of bleeding due to higher unbound active drug
concentration [CORRECT]
,2
Rationale: Warfarin is 99% protein-bound; hypoalbuminemia increases the free
(unbound) fraction, intensifying pharmacological effect and bleeding risk without
changing total drug concentration.
Q3. A patient on carbamazepine for epilepsy starts rifampin for tuberculosis
prophylaxis. Two weeks later, the patient has a breakthrough seizure. This therapeutic
failure is most likely caused by:
A. Rifampin inhibiting CYP3A4, increasing carbamazepine levels
B. Rifampin inducing CYP3A4, increasing carbamazepine metabolism
C. Carbamazepine inhibiting rifampin absorption through chelation
D. Additive hepatotoxicity reducing drug bioavailability
Correct Answer: B. Rifampin inducing CYP3A4, increasing carbamazepine
metabolism [CORRECT]
Rationale: Rifampin is a potent CYP3A4 inducer that accelerates carbamazepine
metabolism, reducing its anticonvulsant efficacy; carbamazepine dose adjustment or
alternative anti-tubercular therapy is required.
Q4. A 65-year-old male with creatinine 1.8 mg/dL (weight 70 kg) is prescribed
gentamicin. The APRN calculates his creatinine clearance using Cockcroft-Gault at
approximately 42 mL/min. Based on this renal function, the APRN should:
A. Initiate standard dosing with therapeutic drug monitoring
B. Reduce the dose and/or extend the dosing interval to prevent accumulation
C. Switch to oral administration to bypass renal excretion
D. Add probenecid to enhance renal tubular secretion
Correct Answer: B. Reduce the dose and/or extend the dosing interval to prevent
accumulation [CORRECT]
Rationale: Aminoglycosides are renally eliminated; CrCl 42 mL/min indicates reduced
clearance requiring dose adjustment to prevent nephrotoxicity and ototoxicity from
drug accumulation.
Q5. An 82-year-old female requires diazepam for muscle spasm. The APRN
recognizes that her advanced age increases the drug's half-life and risk of sedation
due to:
,3
A. Increased hepatic blood flow enhancing first-pass extraction
B. Decreased hepatic mass and reduced CYP450 enzyme activity
C. Increased gastric acid accelerating tablet dissolution
D. Enhanced renal tubular secretion clearing active metabolites faster
Correct Answer: B. Decreased hepatic mass and reduced CYP450 enzyme activity
[CORRECT]
Rationale: Elderly patients have 20-40% reduced hepatic blood flow and CYP450
activity, prolonging diazepam's half-life from 20 hours to 80+ hours and increasing
sedation and fall risk.
Q6. A premenopausal woman is prescribed lamotrigine for bipolar disorder. The
APRN counsels that estrogen-containing oral contraceptives will decrease
lamotrigine levels because estrogen:
A. Inhibits glucuronidation pathways in the liver
B. Induces UGT1A4 enzyme activity, increasing lamotrigine clearance
C. Competes for renal tubular secretion
D. Increases protein binding, reducing free drug fraction
Correct Answer: B. Induces UGT1A4 enzyme activity, increasing lamotrigine
clearance [CORRECT]
Rationale: Estrogen induces UDP-glucuronosyltransferase 1A4 (UGT1A4), the
primary enzyme metabolizing lamotrigine; this interaction requires lamotrigine dose
increases during active contraceptive use and reductions during pill-free intervals.
Q7. A postoperative patient receives morphine 10 mg IV and achieves excellent pain
control. The same patient requires 30 mg oral morphine for equivalent analgesia.
This difference is explained by:
A. The hepatic first-pass effect reducing oral bioavailability to approximately 30%
B. Increased renal clearance of the oral formulation
C. Gastric acid degradation of the oral tablet
D. P-glycoprotein efflux preventing intestinal absorption
Correct Answer: A. The hepatic first-pass effect reducing oral bioavailability to
approximately 30% [CORRECT]
, 4
Rationale: Oral morphine undergoes significant hepatic first-pass metabolism,
yielding approximately 30% bioavailability compared to IV administration; this
necessitates higher oral doses for equivalent therapeutic effect.
Q8. A patient with heart failure is prescribed lisinopril. The APRN understands that
this ACE inhibitor's bioavailability is NOT significantly affected by food because:
A. It undergoes minimal first-pass metabolism
B. It is a prodrug activated by hepatic esterases
C. It is highly lipophilic and absorbed in the distal ileum
D. It is administered sublingually to bypass the GI tract
Correct Answer: A. It undergoes minimal first-pass metabolism [CORRECT]
Rationale: Lisinopril is not a prodrug and is not metabolized by the liver; its
absorption is unaffected by food, though it is incompletely absorbed (approximately
25% bioavailability) due to incomplete intestinal transport.
Q9. A patient with hyperlipidemia is switched from atorvastatin to a generic
formulation. The APRN confirms therapeutic equivalence based on FDA
bioequivalence standards requiring:
A. Identical chemical structure and identical inactive ingredients
B. 90% confidence interval of the ratio of geometric means within 80-125% for AUC
and Cmax
C. Equivalent pill color and shape to ensure patient acceptance
D. Identical half-life regardless of formulation differences
Correct Answer: B. 90% confidence interval of the ratio of geometric means within
80-125% for AUC and Cmax [CORRECT]
Rationale: FDA bioequivalence standards require the 90% confidence interval for the
test/reference ratio of AUC and Cmax to fall within 80-125%; this ensures
pharmacokinetic equivalence without requiring identical inactive ingredients.
Q10. An elderly patient with low muscle mass and increased body fat percentage is
prescribed diazepam. The APRN anticipates a prolonged duration of action because:
A. Increased volume of distribution (Vd) in adipose tissue prolonging elimination
B. Decreased Vd requiring higher loading doses
NR 565 FINAL EXAM ADVANCED PHARMACOLOGY
2026/2027 | 220 Questions with Detailed Verified Answers |
100% Correct | Already Graded A+ | Pass Guaranteed
[Domain 1: Pharmacokinetics & Pharmacodynamics (Questions 1-25)]
[1A: ADME Processes (Absorption, Distribution, Metabolism, Excretion) -
Questions 1-12]
Q1. A 78-year-old patient with atrophic gastritis is prescribed oral vitamin B12
supplementation. The APRN recognizes that this patient's medication absorption will
be significantly impaired due to which physiological change?
A. Increased gastric motility causing rapid transit time
B. Decreased gastric acid production leading to reduced intrinsic factor
C. Increased intestinal blood flow enhancing first-pass metabolism
D. Decreased bile salt production affecting fat-soluble vitamin uptake
Correct Answer: B. Decreased gastric acid production leading to reduced intrinsic
factor [CORRECT]
Rationale: Atrophic gastritis reduces parietal cell mass, decreasing intrinsic factor
secretion required for B12 absorption; options A, C, and D do not accurately describe
the primary pathophysiology of B12 malabsorption in this condition.
Q2. A patient with severe hypoalbuminemia (albumin 2.1 g/dL) is prescribed warfarin.
The APRN anticipates that the free fraction of this highly protein-bound drug will
increase, potentially causing:
A. Decreased therapeutic effect requiring dose escalation
B. Increased risk of bleeding due to higher unbound active drug concentration
C. Reduced hepatic metabolism requiring less frequent dosing
D. Enhanced renal excretion necessitating hydration protocols
Correct Answer: B. Increased risk of bleeding due to higher unbound active drug
concentration [CORRECT]
,2
Rationale: Warfarin is 99% protein-bound; hypoalbuminemia increases the free
(unbound) fraction, intensifying pharmacological effect and bleeding risk without
changing total drug concentration.
Q3. A patient on carbamazepine for epilepsy starts rifampin for tuberculosis
prophylaxis. Two weeks later, the patient has a breakthrough seizure. This therapeutic
failure is most likely caused by:
A. Rifampin inhibiting CYP3A4, increasing carbamazepine levels
B. Rifampin inducing CYP3A4, increasing carbamazepine metabolism
C. Carbamazepine inhibiting rifampin absorption through chelation
D. Additive hepatotoxicity reducing drug bioavailability
Correct Answer: B. Rifampin inducing CYP3A4, increasing carbamazepine
metabolism [CORRECT]
Rationale: Rifampin is a potent CYP3A4 inducer that accelerates carbamazepine
metabolism, reducing its anticonvulsant efficacy; carbamazepine dose adjustment or
alternative anti-tubercular therapy is required.
Q4. A 65-year-old male with creatinine 1.8 mg/dL (weight 70 kg) is prescribed
gentamicin. The APRN calculates his creatinine clearance using Cockcroft-Gault at
approximately 42 mL/min. Based on this renal function, the APRN should:
A. Initiate standard dosing with therapeutic drug monitoring
B. Reduce the dose and/or extend the dosing interval to prevent accumulation
C. Switch to oral administration to bypass renal excretion
D. Add probenecid to enhance renal tubular secretion
Correct Answer: B. Reduce the dose and/or extend the dosing interval to prevent
accumulation [CORRECT]
Rationale: Aminoglycosides are renally eliminated; CrCl 42 mL/min indicates reduced
clearance requiring dose adjustment to prevent nephrotoxicity and ototoxicity from
drug accumulation.
Q5. An 82-year-old female requires diazepam for muscle spasm. The APRN
recognizes that her advanced age increases the drug's half-life and risk of sedation
due to:
,3
A. Increased hepatic blood flow enhancing first-pass extraction
B. Decreased hepatic mass and reduced CYP450 enzyme activity
C. Increased gastric acid accelerating tablet dissolution
D. Enhanced renal tubular secretion clearing active metabolites faster
Correct Answer: B. Decreased hepatic mass and reduced CYP450 enzyme activity
[CORRECT]
Rationale: Elderly patients have 20-40% reduced hepatic blood flow and CYP450
activity, prolonging diazepam's half-life from 20 hours to 80+ hours and increasing
sedation and fall risk.
Q6. A premenopausal woman is prescribed lamotrigine for bipolar disorder. The
APRN counsels that estrogen-containing oral contraceptives will decrease
lamotrigine levels because estrogen:
A. Inhibits glucuronidation pathways in the liver
B. Induces UGT1A4 enzyme activity, increasing lamotrigine clearance
C. Competes for renal tubular secretion
D. Increases protein binding, reducing free drug fraction
Correct Answer: B. Induces UGT1A4 enzyme activity, increasing lamotrigine
clearance [CORRECT]
Rationale: Estrogen induces UDP-glucuronosyltransferase 1A4 (UGT1A4), the
primary enzyme metabolizing lamotrigine; this interaction requires lamotrigine dose
increases during active contraceptive use and reductions during pill-free intervals.
Q7. A postoperative patient receives morphine 10 mg IV and achieves excellent pain
control. The same patient requires 30 mg oral morphine for equivalent analgesia.
This difference is explained by:
A. The hepatic first-pass effect reducing oral bioavailability to approximately 30%
B. Increased renal clearance of the oral formulation
C. Gastric acid degradation of the oral tablet
D. P-glycoprotein efflux preventing intestinal absorption
Correct Answer: A. The hepatic first-pass effect reducing oral bioavailability to
approximately 30% [CORRECT]
, 4
Rationale: Oral morphine undergoes significant hepatic first-pass metabolism,
yielding approximately 30% bioavailability compared to IV administration; this
necessitates higher oral doses for equivalent therapeutic effect.
Q8. A patient with heart failure is prescribed lisinopril. The APRN understands that
this ACE inhibitor's bioavailability is NOT significantly affected by food because:
A. It undergoes minimal first-pass metabolism
B. It is a prodrug activated by hepatic esterases
C. It is highly lipophilic and absorbed in the distal ileum
D. It is administered sublingually to bypass the GI tract
Correct Answer: A. It undergoes minimal first-pass metabolism [CORRECT]
Rationale: Lisinopril is not a prodrug and is not metabolized by the liver; its
absorption is unaffected by food, though it is incompletely absorbed (approximately
25% bioavailability) due to incomplete intestinal transport.
Q9. A patient with hyperlipidemia is switched from atorvastatin to a generic
formulation. The APRN confirms therapeutic equivalence based on FDA
bioequivalence standards requiring:
A. Identical chemical structure and identical inactive ingredients
B. 90% confidence interval of the ratio of geometric means within 80-125% for AUC
and Cmax
C. Equivalent pill color and shape to ensure patient acceptance
D. Identical half-life regardless of formulation differences
Correct Answer: B. 90% confidence interval of the ratio of geometric means within
80-125% for AUC and Cmax [CORRECT]
Rationale: FDA bioequivalence standards require the 90% confidence interval for the
test/reference ratio of AUC and Cmax to fall within 80-125%; this ensures
pharmacokinetic equivalence without requiring identical inactive ingredients.
Q10. An elderly patient with low muscle mass and increased body fat percentage is
prescribed diazepam. The APRN anticipates a prolonged duration of action because:
A. Increased volume of distribution (Vd) in adipose tissue prolonging elimination
B. Decreased Vd requiring higher loading doses
